CPA
SMMT icon

Capital Performance Advisors’s Summit Therapeutics SMMT Stock Holding History

Capital Performance Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-36
Closed -$788 – 2295
2024
Q3 		$788 Buy
+36
New +$503 ﹤0.01% 2032

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Capital Performance Advisors's SMMT Position: Q4 2024 in Review

Capital Performance Advisors sold out of Summit Therapeutics (SMMT) in Q4 2024, closing a stake of 36 shares — an estimated $788 sold.

Capital Performance Advisors first reported a position in SMMT in Q3 2024 and held it in 1 quarter. The position peaked at $788 in Q3 2024. 203 funds tracked by Wall St. Rank hold SMMT as of Q4 2024.

  • Capital Performance Advisors reported no remaining Summit Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 36 Summit Therapeutics shares in Q4 2024, an estimated $788.
  • Capital Performance Advisors first reported a position in Summit Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Summit Therapeutics position peaked at $788 in Q3 2024.
  • 203 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.